Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $78

Benzinga · 18h ago
Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $70 to $78.